The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.
Elisabet StørsetKristine HoleKarsten MidtvedtStein BerganEspen MoldenAnders AsbergPublished in: British journal of clinical pharmacology (2017)
4βOHC does not appear to have a clinical potential to improve individualization of tacrolimus doses early after kidney transplantation.
Keyphrases